drugset / Trial / NCT05445011
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia
Phase 1
Recruiting
12 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PersonGen BioTherapeutics (Suzhou) Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a clinical trial of Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the treatment of patients with relapsed / refractory acute myeloid leukemia. The purpose is to evaluate the safety and efficacy of anti-FLT3 CAR-T cells in patients with relapsed / refractory acute myeloid leukemia.
Timeline
- Start
- 2022-06-14
- Primary completion
- 2025-06-14
- Completion
- 2027-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-FLT3 CAR-T Cell | Cell therapy | 1e+08 cells | — |
| Subject | Anti-FLT3 CAR-T Cell | Cell therapy | 2e+08 cells | — |
| Subject | Anti-FLT3 CAR-T Cell | Cell therapy | 4e+08 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/kg | — |
| Background | Fludarabine | Small molecule | 25 mg/kg | — |